TCT-427 Impact of Treatment Allocation Knowledge on Symptoms: Insights From the Placebo-Controlled ORBITA-CTO Trial
JACC · 2026-11 · 88 (18) · B182
DOI: 10.1016/j.jacc.2026.09.541 ↗Kurz gefasst
Fachartikel in der Zeitschrift JACC, 2026-11. Verfasst von Sarosh Khan und 17 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Khan, S., Sajjad, U., Fawaz, S., Butt, H., Simpson, R., Ibrahim, A., Robertson, C., King, S., Kelly, P., Mohdnazri, S., Cook, C., Demir, O., Spratt, J., Brilakis, E., Shun-Shin, M. J., Al-Lamee, R., Keeble, T., & Davies, J. (2026). TCT-427 Impact of Treatment Allocation Knowledge on Symptoms: Insights From the Placebo-Controlled ORBITA-CTO Trial. JACC, 88(18), B182. https://doi.org/10.1016/j.jacc.2026.09.541
Vancouver
Khan S, Sajjad U, Fawaz S, Butt H, Simpson R, Ibrahim A, et al. TCT-427 Impact of Treatment Allocation Knowledge on Symptoms: Insights From the Placebo-Controlled ORBITA-CTO Trial. JACC. 2026;88(18):B182. doi:10.1016/j.jacc.2026.09.541
BibTeX
@article{Khan2026,
author = {Khan, Sarosh and Sajjad, Uzma and Fawaz, Samer and Butt, Haroun and Simpson, Rupert and Ibrahim, Abdalla and Robertson, Craig and King, Sean and Kelly, Paul and Mohdnazri, Shah and Cook, Christopher and Demir, Ozan and Spratt, James and Brilakis, Emmanouil and Shun-Shin, Matthew J. and Al-Lamee, Rasha and Keeble, Thomas and Davies, John},
title = {TCT-427 Impact of Treatment Allocation Knowledge on Symptoms: Insights From the Placebo-Controlled ORBITA-CTO Trial},
journal = {JACC},
year = {2026},
volume = {88},
number = {18},
pages = {B182},
doi = {10.1016/j.jacc.2026.09.541}
}
EUVIMED